-
EP3145488
European procedure
Extract from the Register of European Patents
EP About this file: EP3145488
| EP3145488 - LIQUID PHARMACEUTICAL COMPOSITION [Right-click to bookmark this link] | Status | Opposition rejected Status updated on 26.07.2024 Database last updated on 01.04.2026 | |
| Former | The patent has been granted Status updated on 19.06.2020 | ||
| Former | Grant of patent is intended Status updated on 26.05.2020 | ||
| Former | Examination is in progress Status updated on 16.03.2018 | ||
| Former | Request for examination was made Status updated on 24.02.2017 | ||
| Former | The international publication has been made Status updated on 16.12.2016 | Most recent event Tooltip | 26.07.2024 | Opposition rejected | published on 28.08.2024 [2024/35] | Applicant(s) | For all designated states Fresenius Kabi Deutschland GmbH Else-Kröner-Strasse 1 61352 Bad Homburg v.d.H. / DE | [2018/30] |
| Former [2017/13] | For all designated states Ares Trading S.A. Zone Industrielle de l'Ouriettaz 1170 Aubonne / CH | Inventor(s) | 01 /
RINALDI, Gianluca Via Silvestrini 9 I-00015 Monterotondo (RM) / IT | 02 /
FRATARCANGELI, Silvia C.so Risorgimento 3 I-03024 Ceprano (FR) / IT | 03 /
DEL RIO, Alessandra Via Ildebrando Vivanti 108 I-00144 Roma / IT | [2017/13] | Representative(s) | D Young & Co LLP 3 Noble Street London EC2V 7BQ / GB | [N/P] |
| Former [2020/30] | D Young & Co LLP 120 Holborn London EC1N 2DY / GB | ||
| Former [2017/13] | Merck Serono S.A. Intellectual Property Zone Industrielle de l'Ouriettaz 1170 Aubonne / CH | Application number, filing date | 15723695.1 | 15.05.2015 | [2017/13] | WO2015EP60818 | Priority number, date | EP20140169755 | 23.05.2014 Original published format: EP 14169755 | [2017/13] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2015177059 | Date: | 26.11.2015 | Language: | EN | [2015/47] | Type: | A1 Application with search report | No.: | EP3145488 | Date: | 29.03.2017 | Language: | EN | The application published by WIPO in one of the EPO official languages on 26.11.2015 takes the place of the publication of the European patent application. | [2017/13] | Type: | B1 Patent specification | No.: | EP3145488 | Date: | 22.07.2020 | Language: | EN | [2020/30] | Search report(s) | International search report - published on: | EP | 26.11.2015 | Classification | IPC: | A61K9/00 | [2017/13] | CPC: |
A61K39/39591 (EP,CN,DK,IL,US);
A61K47/12 (DK,IL,US);
A61K47/26 (DK,IL,US);
A61K9/00 (DK,IL);
A61K9/0019 (EP,DK,IL,US);
A61P1/00 (EP,IL);
A61P1/04 (EP,IL);
A61P17/06 (EP,IL);
A61P19/00 (EP,IL);
A61P19/02 (EP,IL);
A61P29/00 (EP,IL);
A61P37/00 (EP,IL);
A61P37/06 (EP,IL);
C07K16/241 (EP,CN,IL,US);
A61K2039/505 (CN,IL);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2017/13] | Extension states | BA | Not yet paid | ME | Not yet paid | Validation states | MA | Not yet paid | Title | German: | FLÜSSIGE PHARMAZEUTISCHE ZUSAMMENSETZUNG | [2017/13] | English: | LIQUID PHARMACEUTICAL COMPOSITION | [2017/13] | French: | COMPOSITION PHARMACEUTIQUE LIQUIDE | [2017/13] | Entry into regional phase | 16.12.2016 | National basic fee paid | 16.12.2016 | Designation fee(s) paid | 16.12.2016 | Examination fee paid | Examination procedure | 16.12.2016 | Examination requested [2017/13] | 16.12.2016 | Date on which the examining division has become responsible | 15.12.2017 | Amendment by applicant (claims and/or description) | 15.03.2018 | Despatch of a communication from the examining division (Time limit: M04) | 12.04.2018 | Reply to a communication from the examining division | 20.07.2018 | Despatch of a communication from the examining division (Time limit: M04) | 16.10.2018 | Reply to a communication from the examining division | 04.02.2019 | Despatch of a communication from the examining division (Time limit: M04) | 29.05.2019 | Reply to a communication from the examining division | 16.07.2019 | Observations by third parties | 02.03.2020 | Date of oral proceedings | 09.03.2020 | Despatch of a communication from the examining division (Time limit: M02) | 09.03.2020 | Minutes of oral proceedings despatched | 10.03.2020 | Reply to a communication from the examining division | 22.04.2020 | Observations by third parties | 27.05.2020 | Communication of intention to grant the patent | 10.06.2020 | Fee for grant paid | 10.06.2020 | Fee for publishing/printing paid | 10.06.2020 | Receipt of the translation of the claim(s) | Divisional application(s) | EP20186550.8 / EP3741358 | EP21175530.1 / EP3939566 | Opposition(s) | Opponent(s) | 01
22.07.2020
26.04.2021
ADMISSIBLE Biogen Inc. 225 Binney Street Cambridge, MA 02142 / US Opponent's representative Patent Boutique LLP 10A Printing House Yard Hackney Road London E2 7PR / GB | 02
22.07.2020
22.04.2021
WITHDRAWN Samsung Bioepis UK Limited 950 Great West Road Brentford Middlesex TW8 9ES / GB Opponent's representative Patent Boutique LLP 10A Printing House Yard Hackney Road London E2 7PR / GB | 03
22.04.2021
26.04.2021
ADMISSIBLE Samsung Bioepis NL B.V. Olof Palmestraat 10 2616 LR Delft / NL Opponent's representative Patent Boutique LLP 10A Printing House Yard Hackney Road London E2 7PR / GB | [2021/22] |
| Former [2021/16] | |||
| Opponent(s) | 01
22.07.2020
Biogen Inc. 225 Binney Street Cambridge, MA 02142 / US Opponent's representative Patent Boutique LLP 10A Printing House Yard Hackney Road London E2 7PR / GB | ||
| 02
22.07.2020
Samsung Bioepis UK Limited 950 Great West Road Brentford Middlesex TW8 9ES / GB Opponent's representative Patent Boutique LLP 10A Printing House Yard Hackney Road London E2 7PR / GB | |||
| Former [2020/35] | |||
| Opponent(s) | 01
22.07.2020
Biogen Inc. 225 Binney Street Cambridge, MA 02142 / US Opponent's representative Patent Boutique LLP 10A Printing House Yard Hackney Road London E2 7PR / GB | ||
| 02
22.07.2020
Samsung Bioepis UK Limited 950 Great West Road Brentford Middlesex TW8 9ES / GB Opponent's representative Patent Boutique LLP 10A Printing House Yard Hackney Road London E2 7PR / GB | 06.05.2021 | Invitation to proprietor to file observations on the notice of opposition | 13.09.2021 | Reply of patent proprietor to notice(s) of opposition | 15.12.2021 | Cancellation of oral proceeding that was planned for 28.06.2022 | 28.06.2022 | Date of oral proceedings | 26.10.2022 | Date of oral proceedings | 22.12.2022 | Despatch of minutes of oral proceedings | 22.12.2022 | Date of despatch of rejection of opposition | 20.06.2024 | Legal effect of rejection of opposition [2024/35] | Appeal following opposition | 28.02.2023 | Appeal received No. T0466/23 | 28.02.2023 | Payment of appeal fee | 02.05.2023 | Statement of grounds filed | 20.06.2024 | Result of appeal procedure: appeal of the opponent was rejected | 18.07.2024 | Despatch of the decision of the Board of Appeal | 20.06.2024 | Date of oral proceedings | Fees paid | Renewal fee | 10.05.2017 | Renewal fee patent year 03 | 25.04.2018 | Renewal fee patent year 04 | 15.05.2019 | Renewal fee patent year 05 | 15.05.2020 | Renewal fee patent year 06 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | deleted | [2022/23] |
| Former [2021/25] | AL | 22.07.2020 | Cited in | International search | [XY] WO2013164837 (CADILA HEALTHCARE LTD et al.) | [XY] WO2009073569 (ABBOTT LAB et al.) | [XY] US2004033228 (KRAUSE HANS-JUERGEN et al.) | [Y] US2010137213 (FERNANDEZ JASON E et al.) | [XY] US2010278822 (FRAUNHOFER WOLFGANG et al.) [X] 1,2,5-11,15,16 * example - *[Y] 1-16 | [XY] WO2011104381 (NOVO NORDISK AS et al.) [X] 1,2,5,6,8-11,15,16 * page 145, paragraph 1 *[Y] 1-16 | Examination | ZHENG J Y ET AL: "Influence of pH, buffer species, and storage temperature on physicochemical stability of a humanized monoclonal antibody LA298", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER, NL, vol. 308, no. 1-2, 3 February 2006 (2006-02-03), pages 46 - 51, XP027972782, ISSN: 0378-5173, [retrieved on 20060203] | by applicant | WO9729131 | PENNICA, D. ET AL., NATURE, vol. 312, 1984, pages 724 - 729 | DAVIS, J. M. ET AL., BIOCHEMISTRY, vol. 26, 1987, pages 1322 - 1326 | JONES, E. Y. ET AL., NATURE, vol. 338, 1989, pages 225 - 228 | Opposition | IN1606MUM2012 | WO2014039903 | WO2015177057 | WO2015177058 | IN1606MUM2012 | WO2014039903 | WO2015177057 | WO2015177058 | "Alternative buffers for pharmaceutical anti-TNFalpha monoclonal antibody formulations [Elektronische Ressource]", PAPDEOTT002384, 6 February 2013 (2013-02-06), pages 10 pp, XP009188701 | JAMEEL FEROZ ; HERSHENSON SUSAN: "Formulation and Process Development Strategies for Manufacturing Biopharmaceuticals", 26 July 2010, JOHN WILEY & SONS, INC. , Hoboken, N.J. , ISBN: 978-0-470-11812-2, article NICHOLAS W. WARNE: "Formulation Development of Phase 1-2 Biopharmaceuticals: An Efficient and Timely Approach : Jameel/Manufacturing Biopharmaceuticals", pages: 147 - 159, XP055752685, DOI: 10.1002/9780470595886.ch6 DOI: http://dx.doi.org/10.1002/9780470595886.ch6 | "Therapeutic Monoclonal Antibodies: From Bench to Clinic", 1 January 2009, article V. K. SHARMA, ET AL.: "Chapter 30: The Formulation and Delivery of Monoclonal Antibodies", pages: 675 - 709, XP055593299 | "National Formulary", UNITED STATES PHARMACOPEIA, vol. 37, no. 32, 1 May 2014 (2014-05-01), pages 765, 766, 5828, XP055961246 | "Peptides and Proteins as Parenteral Solutions", 1 January 2006, CRC PRESS, article ANONYMOUS: "Pharmaceutical Formulation Development of Peptides and Proteins", pages: 155, XP055961250 | "Formulation and process development strategies for manufacturing biopharmaceuticals.", 26 July 2010, WILEY , New York , ISBN: 9780470118122, article SAMPATHKUMAR KRISHNAN, MONICA M. PALLITTO, MARGARET S. RICCI: "Development of Formulations for Therapeutic Monoclonal Antibodies and Fc Fusion Proteins", pages: 383 - 427, XP055188652, DOI: 10.1002/9780470595886.ch16 DOI: http://dx.doi.org/10.1002/9780470595886.ch16 | "Alternative buffers for pharmaceutical anti-TNFalpha monoclonal antibody formulations [Elektronische Ressource]", PAPDEOTT002384, 6 February 2013 (2013-02-06), pages 10 pp, XP009188701 | JAMEEL FEROZ ; HERSHENSON SUSAN: "Formulation and Process Development Strategies for Manufacturing Biopharmaceuticals", 26 July 2010, JOHN WILEY & SONS, INC. , Hoboken, N.J. , ISBN: 978-0-470-11812-2, article NICHOLAS W. WARNE: "Formulation Development of Phase 1-2 Biopharmaceuticals: An Efficient and Timely Approach : Jameel/Manufacturing Biopharmaceuticals", pages: 147 - 159, XP055752685, DOI: 10.1002/9780470595886.ch6 DOI: http://dx.doi.org/10.1002/9780470595886.ch6 | "Therapeutic Monoclonal Antibodies: From Bench to Clinic", 1 January 2009, article V. K. SHARMA, ET AL.: "Chapter 30: The Formulation and Delivery of Monoclonal Antibodies", pages: 675 - 709, XP055593299 | "National Formulary", UNITED STATES PHARMACOPEIA, vol. 37, no. 32, 1 May 2014 (2014-05-01), pages 765, 766, 5828, XP055961246 | "Peptides and Proteins as Parenteral Solutions", 1 January 2006, CRC PRESS, article ANONYMOUS: "Pharmaceutical Formulation Development of Peptides and Proteins", pages: 155, XP055961250 | "Formulation and process development strategies for manufacturing biopharmaceuticals.", 26 July 2010, WILEY , New York , ISBN: 9780470118122, article SAMPATHKUMAR KRISHNAN, MONICA M. PALLITTO, MARGARET S. RICCI: "Development of Formulations for Therapeutic Monoclonal Antibodies and Fc Fusion Proteins", pages: 383 - 427, XP055188652, DOI: 10.1002/9780470595886.ch16 DOI: http://dx.doi.org/10.1002/9780470595886.ch16 |